Hildebrand P, Beglinger C, Köhler E, Setnikar I, Gyr K
Department of Research, University Hospital, Basel, Switzerland.
Regul Pept. 1987 Aug 17;18(3-4):213-20. doi: 10.1016/0167-0115(87)90009-7.
In conscious dogs we studied the effects of a new cholecystokinin (CCK) antagonist (coded CR 1505) on CCK8-stimulated exocrine pancreatic secretion and release of pancreatic polypeptide (PP). Graded doses of CCK8 (25-400 ng kg-1h-1) were infused i.v. Experiments were repeated against a background infusion of CR 1505 at different doses (0.1, 1 and 10 mg kg-1h-1). The lowest dose of CR 1505 had no biological effects. However, at the upper two doses the compound significantly inhibited the CCK8-stimulated PP release. Furthermore, a significant inhibition of exocrine pancreatic protein secretion was observed with 10 mg kg-1h-1 of CR 1505 (P less than 0.05). The results suggest that CR 1505 could be a useful tool in defining the physiological role of CCK in vivo.
在清醒犬中，我们研究了一种新型胆囊收缩素（CCK）拮抗剂（编码为CR 1505）对CCK8刺激的胰腺外分泌及胰腺多肽（PP）释放的影响。静脉输注不同剂量（25 - 400 ng kg⁻¹h⁻¹）的CCK8。在不同剂量（0.1、1和10 mg kg⁻¹h⁻¹）的CR 1505背景输注下重复进行实验。最低剂量的CR 1505无生物学效应。然而，在较高的两个剂量下，该化合物显著抑制了CCK8刺激的PP释放。此外，当CR 1505剂量为10 mg kg⁻¹h⁻¹时，观察到胰腺外分泌蛋白分泌受到显著抑制（P < 0.05）。结果表明，CR 1505可能是确定CCK在体内生理作用的有用工具。
